Cholera vaccine vaxchora put to the test in immune response study
NCT ID NCT03251495
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested the oral cholera vaccine Vaxchora in 34 healthy adults to see how well it triggers protective antibodies and immune cells. Participants received a single dose, and researchers measured antibody levels, B cells, and T cell responses. The goal is to understand the vaccine's immune effects and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Vaxchora (live attenuated oral cholera vaccine)
- What this could lead to
- If successful, this study could confirm that Vaxchora produces strong immune memory, supporting its use for cholera prevention.
- What could go wrong
- This is a small, early-phase study with only 34 healthy adults, so results may not apply to broader populations. The vaccine may not provide long-lasting protection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLERA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Hope Clinic of Emory University
Atlanta, Georgia, 30030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One dose, big hope: antibiotic may stop cholera in kids
- Cholera vaccine ring strategy tested in bangladesh hotspots
- Simple handwashing program could curb cholera outbreaks
- New cholera drug could cut antibiotic use and hospital stays
- Scientists hunt for cholera protection clues to speed up vaccines
- Soap and sanitation trial aims to slash cholera in congo hotspots